Exelixis
EXEL
#1787
Rank
โ‚น1.012 T
Marketcap
โ‚น3,760
Share price
-0.02%
Change (1 day)
22.92%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

Earnings for Exelixis (EXEL)

Earnings in 2025 (TTM): โ‚น75.60 Billion

According to Exelixis's latest financial reports the company's current earnings are โ‚น2.28 Billion. In 2024 the company made an earning of โ‚น61.94 Billion, an increase over its 2023 earnings that were of โ‚น23.40 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Exelixis from 2000 to 2025

Annual earnings

Year Earnings Change
2025 (TTM) โ‚น75.60 B22.04%
2024 โ‚น61.94 B164.69%
2023 โ‚น23.40 B9.89%
2022 โ‚น21.29 B-20.33%
2021 โ‚น26.73 B124.82%
2020 โ‚น11.89 B-67.14%
2019 โ‚น36.18 B-11.94%
2018 โ‚น41.08 B185.09%
2017 โ‚น14.41 B-325.82%
2016 -โ‚น6.39 Billion-58.12%
2015 -โ‚น15.24 Billion-37.61%
2014 -โ‚น24.43 Billion9.75%
2013 -โ‚น22.26 Billion65.96%
2012 -โ‚น13.41 Billion-291.63%
2011 โ‚น6.99 B-195.59%
2010 -โ‚น7.32 Billion-42.17%
2009 -โ‚น12.66 Billion-18.98%
2008 -โ‚น15.63 Billion-6.99%
2007 -โ‚น16.8 Billion46.3%
2006 -โ‚น11.49 Billion33.25%
2005 -โ‚น8.62 Billion-30.92%
2004 -โ‚น12.48 Billion44.29%
2003 -โ‚น8.65 Billion12.86%
2002 -โ‚น7.66 Billion22.79%
2001 -โ‚น6.24 Billion60.14%
2000 -โ‚น3.9 Billion

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
GlaxoSmithKline
GSK
โ‚น847.29 B 967.56%๐Ÿ‡ฌ๐Ÿ‡ง UK
Sanofi
SNY
โ‚น827.05 B 942.07%๐Ÿ‡ซ๐Ÿ‡ท France
Merck
MRK
โ‚น2.098 T 2,544.02%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
โ‚น730.06 B 819.85%๐Ÿ‡บ๐Ÿ‡ธ USA
Amgen
AMGN
โ‚น749.23 B 844.02%๐Ÿ‡บ๐Ÿ‡ธ USA
Johnson & Johnson
JNJ
โ‚น2.944 T 3,609.65%๐Ÿ‡บ๐Ÿ‡ธ USA
Pfizer
PFE
โ‚น1.077 T 1,257.17%๐Ÿ‡บ๐Ÿ‡ธ USA
Curis
CRIS
-โ‚น2.96 Billion-103.73%๐Ÿ‡บ๐Ÿ‡ธ USA
AVEO Oncology
AVEO
-โ‚น2.64 Billion-103.33%๐Ÿ‡บ๐Ÿ‡ธ USA